Point of view : Challenges in implementation of new immunotherapies for Alzheimer's disease
(2025) In The journal of prevention of Alzheimer's disease 12(1). p.100022-100022- Abstract
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and... (More)
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists. Additionally, there are logistical concerns related to infrastructure, as well as cost-effectiveness and reimbursement issues. This article brings together insights from a diverse group of international researchers and dementia experts and outlines the potential challenges and opportunities, urging all stakeholders to prepare for the introduction of DMTs. We emphasize the need to develop appropriate use criteria, including patient characteristics, specifically for the European healthcare system, to ensure that treatments are administered to the most suitable patients. It is crucial to improve the skills and knowledge of physicians to accurately interpret biomarker results, share decision-making with patients, recognize treatment-related side effects, and monitor long-term treatment. We advocate for investment in patient registries and unbiased follow-up studies to better understand treatment effectiveness, evaluate treatment-related side effects, and optimize long-term treatment. Utilizing amyloid-targeting therapies as a starting point for combination therapies should also be a priority.
(Less)
- author
- Aye, Sandar
; Johansson, Gunilla
; Hock, Christoph
; Lannfelt, Lars
; Sims, John R.
; Blennow, Kaj
; Frederiksen, Kristian S.
; Graff, Caroline
; Molinuevo, José Luis
; Scheltens, Philip
; Palmqvist, Sebastian
LU
; Schöll, Michael
; Wimo, Anders
; Kivipelto, Miia
; Handels, Ron
; Frölich, Lutz
; Zilka, Norbert
; Tolar, Martin
; Johannsen, Peter
; Jönsson, Linus
and Winblad, Bengt
(Less) - organization
- publishing date
- 2025-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, Amyloid-targeting therapies, Challenges in clinical implementation, Disease-modifying treatments
- in
- The journal of prevention of Alzheimer's disease
- volume
- 12
- issue
- 1
- pages
- 1 pages
- publisher
- Elsevier Masson SAS
- external identifiers
-
- pmid:39800469
- scopus:85215355291
- ISSN
- 2274-5807
- DOI
- 10.1016/j.tjpad.2024.100022
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: Copyright © 2024. Published by Elsevier Masson SAS.
- id
- 84ce7317-adfa-420b-ba35-f994dde8a3d1
- date added to LUP
- 2025-05-05 15:18:25
- date last changed
- 2025-05-05 15:19:40
@article{84ce7317-adfa-420b-ba35-f994dde8a3d1,
abstract = {{<p>The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists. Additionally, there are logistical concerns related to infrastructure, as well as cost-effectiveness and reimbursement issues. This article brings together insights from a diverse group of international researchers and dementia experts and outlines the potential challenges and opportunities, urging all stakeholders to prepare for the introduction of DMTs. We emphasize the need to develop appropriate use criteria, including patient characteristics, specifically for the European healthcare system, to ensure that treatments are administered to the most suitable patients. It is crucial to improve the skills and knowledge of physicians to accurately interpret biomarker results, share decision-making with patients, recognize treatment-related side effects, and monitor long-term treatment. We advocate for investment in patient registries and unbiased follow-up studies to better understand treatment effectiveness, evaluate treatment-related side effects, and optimize long-term treatment. Utilizing amyloid-targeting therapies as a starting point for combination therapies should also be a priority.</p>}},
author = {{Aye, Sandar and Johansson, Gunilla and Hock, Christoph and Lannfelt, Lars and Sims, John R. and Blennow, Kaj and Frederiksen, Kristian S. and Graff, Caroline and Molinuevo, José Luis and Scheltens, Philip and Palmqvist, Sebastian and Schöll, Michael and Wimo, Anders and Kivipelto, Miia and Handels, Ron and Frölich, Lutz and Zilka, Norbert and Tolar, Martin and Johannsen, Peter and Jönsson, Linus and Winblad, Bengt}},
issn = {{2274-5807}},
keywords = {{Alzheimer's disease; Amyloid-targeting therapies; Challenges in clinical implementation; Disease-modifying treatments}},
language = {{eng}},
month = {{01}},
number = {{1}},
pages = {{100022--100022}},
publisher = {{Elsevier Masson SAS}},
series = {{The journal of prevention of Alzheimer's disease}},
title = {{Point of view : Challenges in implementation of new immunotherapies for Alzheimer's disease}},
url = {{http://dx.doi.org/10.1016/j.tjpad.2024.100022}},
doi = {{10.1016/j.tjpad.2024.100022}},
volume = {{12}},
year = {{2025}},
}